Hennion & Walsh Asset Management Inc. Takes Position in Telix Pharmaceuticals Limited $TLX

Key Points

• Hennion & Walsh Asset Management initiated a position in Telix Pharmaceuticals, purchasing 150,138 shares valued at approximately $1.73 million during the second quarter. Several other institutional investors also established or increased positions.
• Analyst sentiment remains generally positive, with Telix carrying a consensus “Moderate Buy” rating and an average price target of $20.40, although some firms recently downgraded the stock or issued a sell rating.
• TLX opened at $12.00 and was up 1.8%, near its 52-week high of $12.60. Telix develops targeted radiopharmaceuticals for cancer diagnosis and treatment.

Hennion & Walsh Asset Management Inc. bought a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 150,138 shares of the company's stock, valued at approximately $1,731,000.

A number of other large investors have also recently made changes to their positions in TLX. Russell Investments Group Ltd. bought a new position in Telix Pharmaceuticals during the 2nd quarter valued at about $975,000. Jane Street Group LLC bought a new stake in Telix Pharmaceuticals in the second quarter worth about $564,000. IHT Wealth Management LLC purchased a new position in shares of Telix Pharmaceuticals during the second quarter valued at approximately $213,000. Rhumbline Advisers boosted its position in shares of Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock valued at $25,000 after buying an additional 1,392 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in shares of Telix Pharmaceuticals during the third quarter valued at approximately $243,000.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TLX shares. HC Wainwright reissued a "buy" rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Tuesday, July 7th. Citigroup reduced their target price on Telix Pharmaceuticals from $22.50 to $22.00 and set a "buy" rating on the stock in a research note on Tuesday, July 7th. Wedbush reiterated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research report on Monday, July 6th. Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Friday, July 17th. Finally, Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an "outperform" rating to a "sector perform" rating in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Telix Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $20.40.

Telix Pharmaceuticals Stock Up 1.8%

TLX opened at $12.00 on Wednesday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The stock's fifty day moving average is $10.55 and its two-hundred day moving average is $9.43. Telix Pharmaceuticals Limited has a 52 week low of $6.28 and a 52 week high of $12.60.

Telix Pharmaceuticals Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source